益心舒片联合伊伐布雷定治疗慢性稳定型心绞痛的临床研究
|
摘要
目的观察益心舒片联合盐酸伊伐布雷定片治疗慢性稳定型心绞痛的临床疗效。方法选取2015年12月—2017年12月中国人民武装警察8650部队医院收治的100例慢性稳定型心绞痛患者作为研究对象,所有患者根据随机对照原则分为对照组(50例)和治疗组(50例)。对照组患者口服盐酸伊伐布雷定片,1片/次,2次/d;治疗组患者在对照组基础上口服益心舒片,3片/次,3次/d。两组患者均连续治疗12周。观察两组患者的临床疗效,比较两组治疗前后的心绞痛频率、持续时间、西雅图心绞痛量表(SAQ)评分、血清生化指标。结果治疗后,治疗组总有效率为94.00%,显著高于对照组的78.00%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者心绞痛发作次数和持续时间均较明显降低,而SAQ评分显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组心绞痛发作次数、持续时间和SAQ评分显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者内皮素-1(ET-1)、可溶性CD40配体(sCD40L)水平均明显降低,而降钙素基因相关肽(CGRP)水平显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组各指标显著优于对照组,两组比较差异具有统计学意义(P<0.05)。结论益心舒片联合盐酸伊伐布雷定片治疗慢性稳定型心绞痛具有较好的临床疗效,能够明显改善患者临床症状和血清生化指标,具有一定的临床推广应用价值。
Objective To observe the clinical efficacy of Yixinshu Tablets combined with Ivabradine Hydrochloride Tablets in treatment of chronic stable angina pectoris. Methods Patients(100 cases) with chronic stable angina pectoris in People's Armed Police 8650 Military Hospital from December 2015 to December 2017 were randomly divided into the control group(50 cases) and treatment group(50 cases). Patients in the control group were po administered with Ivabradine Hydrochloride Tablets, 1 tablet/time,twice daily. Patients in the treatment group were po administered with Yixinshu Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the angina frequency, duration, SAQ scores, and serum biochemical indicators in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the treatment group was 94.00%, which was significantly higher than 78.00% in the control group, and there were differences between two groups(P < 0.05). After treatment, angina frequency and duration in two groups were significantly decreased, but SAQ scores were increased, and the difference was statistically significant in the same group(P <0.05). And angina frequency, duration and SAQ scores in the treatment group were significantly better than those in the control group,with significant difference between two groups(P < 0.05). After treatment, ET-1 and sCD40L levels in two groups were significantly decreased, but CGRP levels were increased, and the difference was statistically significant in the same group(P < 0.05). And those indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Yixinshu Tablets combined with Ivabradine Hydrochloride Tablets has good clinical efficacy in treatment of chronic stable angina pectoris, can significantly improve the clinical symptoms and serum biochemical indexes, which has a high clinical research value.
Objective To observe the clinical efficacy of Yixinshu Tablets combined with Ivabradine Hydrochloride Tablets in treatment of chronic stable angina pectoris. Methods Patients(100 cases) with chronic stable angina pectoris in People's Armed Police 8650 Military Hospital from December 2015 to December 2017 were randomly divided into the control group(50 cases) and treatment group(50 cases). Patients in the control group were po administered with Ivabradine Hydrochloride Tablets, 1 tablet/time,twice daily. Patients in the treatment group were po administered with Yixinshu Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the angina frequency, duration, SAQ scores, and serum biochemical indicators in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the treatment group was 94.00%, which was significantly higher than 78.00% in the control group, and there were differences between two groups(P < 0.05). After treatment, angina frequency and duration in two groups were significantly decreased, but SAQ scores were increased, and the difference was statistically significant in the same group(P <0.05). And angina frequency, duration and SAQ scores in the treatment group were significantly better than those in the control group,with significant difference between two groups(P < 0.05). After treatment, ET-1 and sCD40L levels in two groups were significantly decreased, but CGRP levels were increased, and the difference was statistically significant in the same group(P < 0.05). And those indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Yixinshu Tablets combined with Ivabradine Hydrochloride Tablets has good clinical efficacy in treatment of chronic stable angina pectoris, can significantly improve the clinical symptoms and serum biochemical indexes, which has a high clinical research value.
引文
[1]徐凤芹.慢性稳定性心绞痛的中西医诊断与治疗[J].中国中西医结合杂志,2009,29(6):572-576.
[2]于怡卉,李明慧,许周涛,等.伊伐布雷定在心血管疾病中的研究新进展[J].中华临床医师杂志:电子版,2014,8(14):2721-2724.
[3]方显明,杨建设,伟钢林,等.益心脉颗粒对心肌缺血再灌注损伤心功能的影响[J].广州中医药大学学报,2002,19(4):298-301.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[5]陈贵廷,薛赛琴.最新国内外疾病诊疗标准[M].北京:学苑出版社,1991:214-215.
[6]刘淑红.西雅图心绞痛量表(SAQ)中文译本的信度、效度、反应度[D].天津:天津医科大学,2003.
[7]王新刚,蒋捷,贾佳,等.中国慢性稳定性心绞痛患者抗心绞痛治疗现状[J].中国循环杂志,2014,29(z1):8.
[8]吴怀瑞.慢性稳定型心绞痛的治疗进展[J].中国乡村医药,2009,16(9):78-79.
[9]侯鹏高,吕长淮.伊伐布雷定药理机制研究概述[J].齐齐哈尔医学院学报,2015,36(20):3071-3072.
[10]李春岩,史载祥.益心舒胶囊治疗冠心病心绞痛的临床研究进展[J].中西医结合心脑血管病杂志,2013,11(3):351-352.
[11]唐杨章,林桂英,冯志强.不稳定性心绞痛患者血浆内皮素与血小板聚集的关系[J].现代医药卫生,2002,18(5):366-367.
[12]王建安,傅雷,杜同信,等.降钙素基因相关肽及内皮素水平与冠心病关系的研究[J].江苏医药,2001,27(10):789.
[13]刘建萍,葛郁芝,曾黎峰,等.可溶性CD40配体与急性冠状动脉综合征的关系[J].中国心血管病研究,2006,4(8):565-567.
[2]于怡卉,李明慧,许周涛,等.伊伐布雷定在心血管疾病中的研究新进展[J].中华临床医师杂志:电子版,2014,8(14):2721-2724.
[3]方显明,杨建设,伟钢林,等.益心脉颗粒对心肌缺血再灌注损伤心功能的影响[J].广州中医药大学学报,2002,19(4):298-301.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[5]陈贵廷,薛赛琴.最新国内外疾病诊疗标准[M].北京:学苑出版社,1991:214-215.
[6]刘淑红.西雅图心绞痛量表(SAQ)中文译本的信度、效度、反应度[D].天津:天津医科大学,2003.
[7]王新刚,蒋捷,贾佳,等.中国慢性稳定性心绞痛患者抗心绞痛治疗现状[J].中国循环杂志,2014,29(z1):8.
[8]吴怀瑞.慢性稳定型心绞痛的治疗进展[J].中国乡村医药,2009,16(9):78-79.
[9]侯鹏高,吕长淮.伊伐布雷定药理机制研究概述[J].齐齐哈尔医学院学报,2015,36(20):3071-3072.
[10]李春岩,史载祥.益心舒胶囊治疗冠心病心绞痛的临床研究进展[J].中西医结合心脑血管病杂志,2013,11(3):351-352.
[11]唐杨章,林桂英,冯志强.不稳定性心绞痛患者血浆内皮素与血小板聚集的关系[J].现代医药卫生,2002,18(5):366-367.
[12]王建安,傅雷,杜同信,等.降钙素基因相关肽及内皮素水平与冠心病关系的研究[J].江苏医药,2001,27(10):789.
[13]刘建萍,葛郁芝,曾黎峰,等.可溶性CD40配体与急性冠状动脉综合征的关系[J].中国心血管病研究,2006,4(8):565-567.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |